Profusa (NVACW) Non-Current Deferred Tax Liability (2022 - 2023)
Profusa (NVACW) reported Non-Current Deferred Tax Liability of $13661.0 for Q4 2023, down 63.02% on a YoY basis from $36940.0 in Q4 2022, and down 98.92% quarter-over-quarter from $1.3 million in Q3 2023.
Profusa (NVACW) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Profusa has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $13661.0 in Q4 2023.
- For the quarter ending Q4 2023, Non-Current Deferred Tax Liability fell 63.02% year-over-year to $13661.0; the trailing twelve-month figure through Dec 2023 stood at $13661.0 (down 63.02% YoY), and the FY2023 full-year result was $13661.0, down 63.02% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2023 stood at $13661.0, down from $1.3 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.3 million in Q3 2023, with the low at $13661.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Profusa | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13,661.00 |
| Dec 31, 2023 | 13,661.00 |
| Sep 30, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 735,048.00 |
| Jun 30, 2023 | 735,048.00 |
| Dec 31, 2022 | 36,940.00 |
| Dec 31, 2022 | 36,940.00 |